Translate page

The 2015 iCMLf Rowley Prize is awarded to Professor Richard Van Ettenvan etten richard

February 2015 - The iCMLf Rowley Prize is designed to recognise persons who have made major contributions to the understanding of the biology of CML. In 2015 the Rowley Prize is awarded to Professor Richard Van Etten. This iCMLf award recognises Dr Van Etten’s groundbreaking research focusing on the development of new therapeutic strategies such as the tyrosine kinase inhibitors.  

Patient Education: two useful resources to share with your CML patients

October 2014 - ‘Patient education is an essential supplement to good professional healthcare.’* With the on going success of TKI therapies and greater numbers of CML patients remaining on treatment, many for life, people who have an interest in self-education will continue to grow. Patient specific educational resources are very valuable and we share two of these with you today. We hope these are useful, not only for our members who are patients and or patient advocates, but also for physicians around the world to share with their patients.

iCMLf Annual Report - what has the iCMLf accomplished in the last 12 months?

September 2014 - We are delighted to present the iCMLf Annual Report 2013/2014. It features the Foundation’s activities from Sept 1st 2013 to August 31st 2014.iCMLf Annual Report 2013 2014

Key outcomes from the iCMLf in the last 12 months include:

  • With 22 personalised preceptorships at 11 CML centres of excellence the iCMLf Clinical Preceptorship Program continues to have far reaching and long-term impact on the management of CML.
  • The iCMLf Diagnosis and Testing program to build local, sustainable capacity for CML diagnostics has been widely extended by funding 9 Phase I projects and 4 Phase II projects this year.
  • Visitors to the iCMLf website came from 80% of all countries around the world. With 130,000 page impressions per month and over 24,000 visitors per month the iCMLf website goes a long way to address
a global audience.
  • Cases in the interactive online Clinical Case Discussion Forum have had over 16,000 views this year.

New Structure and a Fresh Look: the iCMLf Website is relaunchedScreenshot Homepage 

August 2014 - The iCMLf has relaunched its website. Programs, discussions and education on this interactive platform now have a new structure and a fresh new look to make the multi-layered content more accessible. We invite you to see and look for yourself on a tour around the new website.

Truly global in focus - Interview with Timothy Hughes, chair of the iCMLf

NEW PHOTO Hughes T 02-mod2 Kopie 2

July 2014 - “We wanted to spread the benefit of new knowledge, effective drugs and accurate monitoring beyond the developed world. This was our first and is still our highest priority”. (Tim Hughes)

Q1: Great advances have been made in the management of patients with CML during the last couple of years. Where do you currently still see the biggest challenges and how could we best meet those challenges?

The outlook for a newly diagnosed CML patient is very positive in 2014 – a complete turnaround from the situation they faced even in the 1990s. However we still see CML patients transform into blast crisis in the first one or two years of kinase inhibitor therapy. We must find ways to identify these patients before they transform and trial innovative approaches. This remains one of our biggest challenges.

The inaugural iCMLf Goldman Prize is awarded to Professor RüdigerHehlmann Portraitfoto 2012 Hehlmann

February, 2014 - In addition to the Rowley Prize that the iCMLf awards annually to individuals that have made a major lifetime contribution to the understanding of the biology of CML, the iCMLf Directors have created a second prize. The recently launched Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. The new award has been created in memory of the late iCMLf chair to honour Professor Goldman´s commitment to clinical excellence in treating CML.